Literature DB >> 29304921

Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma.

Morie A Gertz1, Francis K Buadi2, Suzanne R Hayman3, Martha Q Lacy4, Angela Dispenzieri4, David Dingli4, Wilson I Gonsalves4, Shaji Kumar4, Prashant Kapoor2, Taxiarchis Kourelis2, William J Hogan2.   

Abstract

Systems have been put in place in the Mayo Clinic Stem Cell Transplantation program to reduce day-100 all-cause mortality. Currently our mortality has been reduced to 0.3%. Patients can undergo transplant as an outpatient, with a median hospital duration of 0 days and only 25% of patients requiring a hospital stay of 5 days or greater. Outpatient transplantation is safe and reduces patient-incurred costs.
Copyright © 2017 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2018        PMID： 29304921     DOI： 10.1016/j.mayocp.2017.09.012

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


  6 in total

Review 1.  Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population.

Authors:  Saurabh Zanwar; Jithma Prasad Abeykoon; Prashant Kapoor
Journal:  Curr Hematol Malig Rep       Date:  2019-04       Impact factor: 3.952

Review 2.  Initial Therapeutic Approaches to Patients with Multiple Myeloma.

Authors:  Hadi E Berbari; Shaji K Kumar
Journal:  Adv Ther       Date:  2021-06-18       Impact factor: 3.845

3.  Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealand myeloma and related diseases registry (MRDR).

Authors:  Krystal Bergin; Cameron Wellard; Bradley Augustson; Rachel Cooke; Hilary Blacklock; Simon J Harrison; Joy Ho; Tracy King; Hang Quach; Peter Mollee; Patricia Walker; Elizabeth Moore; Zoe McQuilten; Erica Wood; Andrew Spencer
Journal:  Bone Marrow Transplant       Date:  2021-05-19       Impact factor: 5.483

4.  Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma.

Authors:  Kevin C Miller; Morie A Gertz; Francis K Buadi; Suzanne R Hayman; Robert C Wolf; Martha Q Lacy; Angela A Dispenzieri; David Dingli; Prashant Kapoor; Wilson I Gonsalves; Taxiarchis Kourelis; William J Hogan; Shaji K Kumar
Journal:  Bone Marrow Transplant       Date:  2018-08-16       Impact factor: 5.483

5.  Safety and feasibility of outpatient autologous stem cell transplantation in pediatric patients with primary central nervous system tumors.

Authors:  Jane Koo; Stacy Silverman; Brandon Nuechterlein; Amy K Keating; Michael R Verneris; Nicholas K Foreman; Jean M Mulcahy Levy
Journal:  Bone Marrow Transplant       Date:  2019-02-19       Impact factor: 5.483

Review 6.  Multiple Myeloma Outpatient Transplant Program in the Era of Novel Agents: State-of-the-Art.

Authors:  Massimo Martino; Annalisa Paviglianiti; Mara Memoli; Giovanni Martinelli; Claudio Cerchione
Journal:  Front Oncol       Date:  2020-11-11       Impact factor: 6.244
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.